These data clearly demonstrate that PARP plays a significant role in the Middle Eastern BC pathogenesis and its combined inhibition with XIAP may expand the role of PARP inhibition therapy beyond BRCA-deficient BCs. This evidence concerns the gene XIAP and breast cancer.